Roche Holding AG (RHHBY)
| Market Cap | 236.15B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.52B |
| EPS (ttm) | 2.03 |
| PE Ratio | 17.85 |
| Forward PE | 12.08 |
| Dividend | $1.29 (3.55%) |
| Ex-Dividend Date | Mar 16, 2023 |
| Volume | 805,730 |
| Open | 36.17 |
| Previous Close | 35.81 |
| Day's Range | 36.11 - 36.38 |
| 52-Week Range | 31.77 - 40.84 |
| Beta | 0.19 |
| Analysts | Hold |
| Price Target | 40.00 (+10.41%) |
| Earnings Date | n/a |
About RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, cardiovascular, diabetes, Covid-19, hepatitis, human papillomavirus, and other disease... [Read more]
Financial Performance
In 2022, RHHBY's revenue was 63.28 billion, an increase of 0.76% compared to the previous year's 62.80 billion. Earnings were 13.53 billion, a decrease of -9.40%.
Financial numbers in CHF Financial StatementsAnalyst Forecast
According to one analyst, the rating for RHHBY stock is "Hold" and the 12-month stock price forecast is $40.0.
News
Roche to buy part of LumiraDx diagnostics platform for $295 million
Swiss drugmaker Roche said on Friday it has agreed to buy LumiraDx's Point of Care diagnostics platform business for about $295 million.
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
Basel, 29 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group (NASDAQ GS: LMDX) related to LumiraDx's...
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted, under Priority Review, the company's supplemental Biologics ...
FDA Grants Priority Review to Xolair (omalizumab) for Children and Adults With Food Allergies Based on Positive National Institutes of Health Phase III Study Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted, under ...
Roche navify digital solutions get excellent ratings from healthcare professionals in KLAS Research reports
Healthcare professionals greatly value navify Tumor Board for improving tumour board meeting experiences, offering a holistic view of data, facilitating multidisciplinary team collaboration and optimi...
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices The ranking acknowledges Roche's commitment to sustainability as an integral part of its busin...
New data for Roche's Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were pre...
New Data for Genentech's Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody p...
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech's Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced t...
New data reinforce the benefit of early preventative treatment with Roche's Hemlibra for babies with severe haemophilia A
Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in pr...
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breas...
Genentech's Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today positive results from the Phase III INAVO120 study evaluating inavoli...
Roche's inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulv...
Genentech's Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III KATHERI...
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
Basel, 5 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III INAVO120 study of the investigational therapy, inavolisib, in combination with palbocicl...
Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III INAVO120 study of the investigati...
Roche Buys Carmot Therapeutics to Compete in Booming Market for Weight-Loss Drugs
Roche Holding AG is the latest drug maker trying to take advantage of the booming demand for weight-loss drugs.
Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal
Roche said Carmot Therapeutics' research and development portfolio “has great potential to treat obesity, diabetes and potentially other diseases” both on its own and in combination with Roche's asset...
Roche targets oral obesity drugs with Carmot takeover
Teresa Graham, CEO of Roche Pharmaceuticals, says its takeover of anti obesity drug developer Carmot Therapeutics will bolster the company's weight-loss treatments, including via potential oral pills.
Roche is buying Carmot to enter anti-obesity market
Roche Holding AG Genussscheine (SWX: ROG) says it will acquire Carmot Therapeutics for $2.7 billion in cash. Its shares are up 3.0% at writing.
Roche enters obesity market with Carmot takeover but drugs may not be available until 2030
Roche is to acquire anti obesity drug developer Carmot Therapeutics, becoming the latest pharma company to enter the global weight-loss drugs market.
Roche Strikes $3.1 Billion Deal for Obesity Drugmaker. It Hopes to Compete with Eli Lilly, Novo Nordisk.
Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion. The Swiss company is hoping to join Eli Lilly and Novo Nordisk at the forefront of the weight-loss drug marke...
Roche Acquiring Obesity Drug Maker Carmot for $3.1 Billion
Roche Holding AG will pay as much as $3.1 billion for Carmot Therapeutics Inc., in a deal that includes three experimental medicines in obesity and diabetes. Eric Pfanner reports on Bloomberg Televisi...